NCT04905602View on ClinicalTrials.gov

A Trial of SHR-1905 in Healthy Subjects and Subjects With Mild Asthma

PHASE1CompletedINTERVENTIONAL
Enrollment

86

Participants

Timeline

Start Date

June 15, 2021

Primary Completion Date

October 9, 2023

Study Completion Date

October 9, 2023

Conditions
Asthma
Interventions
DRUG

SHR-1905/placebo

"Drug: SHR-1905 subcutaneous, single dose~Drug: Placebo subcutaneous, single dose"

Trial Locations (1)

200031

Shanghai Xuhui Central Hospital, Shanghai

All Listed Sponsors
lead

Shanghai Hengrui Pharmaceutical Co., Ltd.

INDUSTRY